Larin Fe 1.5/30 Kit
NDC Package 16714-405-03

11-digit billing NDC: 16714040503

Package Information

Larin Fe 1.5/30 (norethindrone acetate/ethinyl estradiol and ferrous fumarate) kits is lARINTM Fe 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.Oral contraceptives are highly effective. This formulation utilizes a kit delivery system. Marketed by Northstar Rx Llc, this product is identified by NDC 16714-405 and is authorized under FDA application ANDA091453.

Identification & Billing

NDC Package Code
16714-405-03
Package Description
3 BLISTER PACK in 1 CARTON / 1 KIT in 1 BLISTER PACK
Product Code
11-Digit Billing Format
16714040503
RxNorm Crosswalk
  • RxCUI: 1359022 - norethindrone acetate 1.5 MG / ethinyl estradiol 30 MCG Oral Tablet
  • RxCUI: 1359022 - ethinyl estradiol 0.03 MG / norethindrone acetate 1.5 MG Oral Tablet
  • RxCUI: 1359022 - ethinyl estradiol 30 MCG / norethindrone acetate 1.5 MG Oral Tablet
  • RxCUI: 1359023 - {21 (ethinyl estradiol 0.03 MG / norethindrone acetate 1.5 MG Oral Tablet) / 7 (ferrous fumarate 75 MG Oral Tablet) } Pack
  • RxCUI: 1359023 - Eth estra-Noreth Ac 0.03-1.5 MG (21) Oral Tablet / Ferr fum 75 MG (7) Oral Tablet 28 Day Pack

Clinical Specifications

Proprietary Name
Larin Fe 1.5/30
Non-Proprietary Name
Norethindrone Acetate/ethinyl Estradiol And Ferrous Fumarate
Dosage Form
Kit - A packaged collection of related material.
Usage Information
LARINTM Fe 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.TABLE I: LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD% of Women Experiencing an Unintended Pregnancy in the First Year of Continuous UseMethodLowest Expected*Typical**(No contraception)(85)(85)Oral contraceptives combined progestin only 0.1 0.53 N/A*** N/A***Diaphragm with spermicidal cream or jelly620Spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film)626Vaginal Sponge nulliparous parous 9 20 20 40Implant0.050.05Injection: depot medroxyprogesterone acetate0.30.3IUD progesterone T copper T 380A LNg 20 1.5 0.6 0.1 2.0 0.8 0.1Condom without spermicides female male 5 3 21 14Cervical Cap with spermicidal cream or jelly nulliparous parous 9 26 20 40Periodic abstinence (all methods)1-925Withdrawal419Female sterilization0.50.5Male sterilization0.100.15Adapted from RA Hatcher et al, Reference 7.* The authors' best guess of the percentage of women expected to experience an accidental pregnancy amongcouples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason.**This term represents “typical” couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason.***N/A--Data not available.

Regulatory & Marketing

Labeler Name
Northstar Rx Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA091453
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-23-2013
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (16714-405). Click a package code to view its specific billing and regulatory data.

1 BLISTER PACK in 1 PACKET / 1 KIT in 1 BLISTER PACK
1 BLISTER PACK in 1 CARTON / 1 KIT in 1 BLISTER PACK
6 BLISTER PACK in 1 CARTON / 1 KIT in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 16714-405-03 identifies a specific commercial package of 3 blister pack in 1 carton / 1 kit in 1 blister pack of Larin Fe 1.5/30, a human prescription drug labeled by Northstar Rx Llc. This kit is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Northstar Rx Llc on August 23, 2013. The current certification is valid through December 31, 2026.

How is this Northstar Rx Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 16714040503. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
16714-405-03
11-Digit CMS (5-4-2)
16714-0405-03

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.